← Back to Search

GraphoLearn Reading Intervention for Dyslexia

N/A
Recruiting
Led By Nicole Landi, PhD
Research Sponsored by University of Connecticut
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must be 6.0 to 10.0 years old
Must be a native speaker of English
Must not have
Major depressive disorder
Any neurologic impairment that limits the ability to use a keyboard or mouse, or to touch a screen
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessment is given before and after the intervention, ~12 weeks apart; the assessment will also be re-administered after a 12 week retention period.
Awards & highlights
No Placebo-Only Group

Summary

This trial will examine the effectiveness of a home-administered technology-based treatment for reading disability in children ages 6.0-10.0. The experimenters will recruit 450 children with reading difficulty from the Healthy Brain Network and compare reading skills before and after a 12-week GraphoLearn reading intervention relative to an active (math) control.

Who is the study for?
This trial is for children aged 6 to 10 who are part of the Healthy Brain Network, have reading difficulties as shown by specific test scores, and can speak English natively. They must be able to use a keyboard or mouse and not have severe vision or hearing issues, certain psychiatric conditions like psychosis or major depression, nor moderate to severe autism.
What is being tested?
The study tests how effective GraphoLearn (a tech-based reading treatment) is compared to a math control intervention in improving reading skills over a period of 12 weeks. It includes follow-up assessments after another 12 weeks without treatment to check if improvements last.
What are the potential side effects?
Since this trial involves educational technology interventions rather than medical treatments, traditional side effects are not applicable. However, participants may experience fatigue or frustration during the learning process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 6 and 10 years old.
Select...
I am a native English speaker.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with major depressive disorder.
Select...
I have difficulty using a keyboard, mouse, or touchscreen due to a neurological condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessment is given before and after the intervention, ~12 weeks apart; the assessment will also be re-administered after a 12 week retention period.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessment is given before and after the intervention, ~12 weeks apart; the assessment will also be re-administered after a 12 week retention period. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Test of Word Reading Efficiency (TOWRE II), total word reading efficiency (TWRE) measure
Secondary study objectives
Articulation Disorders
Phonological Awareness (PA), Phonological Memory, (PM) and Rapid Naming (RN), which are composite scores and will be assessed with the Comprehensive Test of Phonological Processing (CTOPP-II)
Woodcock Johnson Tests of Achievement (WJ-IV), Letter Word identification (ID) and Word Attack subtests.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: GraphoLearn reading interventionExperimental Treatment1 Intervention
GraphoLearn is a research-based treatment, delivered as an engaging computer game. Players match auditory targets (e.g., phonemes, rimes) to visual targets (single letters, letter sequences, words). The complexity of the items within each level is ordered such that at each level, the most frequent and regular mappings are introduced first based on measures such as orthographic/phonological neighborhood size and morphological family size. GraphoLearn allows the children to practice and reinforce lessons at their own individual trial pace and provides a record of performance progress that can be used to guide analyses.
Group II: Vektor math controlActive Control1 Intervention
We selected an active control to maximize the specificity of the treatment outcomes; to this end, math games are among the most commonly used. Game sessions support learning numerical mathematical skills and cognition related to mathematical skills. In addition to math, this game contains training tasks for visuospatial working memory, spatial visualization and visuospatial reasoning. The overall theme of the game and feedback style are similar to those in GraphoLearn.

Find a Location

Who is running the clinical trial?

Haskins LaboratoriesUNKNOWN
1 Previous Clinical Trials
30 Total Patients Enrolled
Child Mind InstituteOTHER
2 Previous Clinical Trials
724 Total Patients Enrolled
University of ConnecticutLead Sponsor
191 Previous Clinical Trials
160,382 Total Patients Enrolled
Georgia State UniversityOTHER
65 Previous Clinical Trials
30,256 Total Patients Enrolled
2 Trials studying Dyslexia
68 Patients Enrolled for Dyslexia
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,067 Previous Clinical Trials
2,747,014 Total Patients Enrolled
10 Trials studying Dyslexia
5,644 Patients Enrolled for Dyslexia
Nicole Landi, PhDPrincipal Investigator - University of Connecticut
University of Connecticut

Media Library

GraphoLearn reading intervention Clinical Trial Eligibility Overview. Trial Name: NCT04568824 — N/A
Dyslexia Research Study Groups: GraphoLearn reading intervention, Vektor math control
Dyslexia Clinical Trial 2023: GraphoLearn reading intervention Highlights & Side Effects. Trial Name: NCT04568824 — N/A
GraphoLearn reading intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT04568824 — N/A
Dyslexia Patient Testimony for trial: Trial Name: NCT04568824 — N/A
~76 spots leftby Nov 2025